home / stock / frln / frln news

FRLN News and Press, Freeline Therapeutics Holdings plc From 05/12/21

Stock Information
Company Name: Freeline Therapeutics Holdings plc
Stock Symbol: FRLN
Market: NASDAQ
Website: freeline.life
Menu
FRLN FRLN Quote FRLN Short FRLN News FRLN Articles FRLN Message Board
Get FRLN Alerts

News, Short Squeeze, Breakout and More Instantly...
FRLN - Freeline to Participate at the 2021 RBC Capital Markets Global Healthcare Conference

LONDON, May 12, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV gene therapies for patients suffering from inherited systemic debilitati...
FRLN - Freeline Presents Data Highlighting Platform Technology at the American Society of Gene and Cell Therapy Annual Meeting 2021

LONDON, May 11, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative gene therapies for patients suffering from inherited systemic debilitating d...

FRLN - BCRX, WW, FSLY and YELL among midday movers

Gainers: SemiLEDs (LEDS) +106%.Lexaria Bioscience (LEXX) +49%.Stealth BioTherapeutics (MITO) +38%.Liquidity Services (LQDT) +27%.Applied UV (AUVI) +25%.BioCryst Pharmaceuticals (BCRX) +21%.Avid Technology (AVID) +21%.Summit Wireless Technologies (WISA) +20%.WW International (WW) +20...

FRLN - Freeline to Present Data at the American Society of Gene and Cell Therapy Annual Meeting 2021

LONDON, April 27, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative gene therapies for patients suffering from inherited systemic debilitating...
FRLN - Freeline to Participate in Upcoming Investor Conferences in April and May 2021

LONDON, April 21, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering from inherited systemic...

FRLN - Freeline Therapeutics EPS misses by $3.24

Freeline Therapeutics (FRLN): FY GAAP EPS of -$6.81 misses by $3.24.Cash and cash equivalents of $230M.Press Release For further details see: Freeline Therapeutics EPS misses by $3.24

FRLN - Freeline Reports Full Year 2020 Financial Results and Business Highlights

Plans to have three AAV gene therapy programs in the clinic by year-end 2021 Data from FLT180a Phase 1/2 trial for Hemophilia B demonstrated potential for durable normalization of Factor IX activity Strong 2020 year-end cash position of $230 million funds key upcoming cl...
FRLN - Mizuho initiates Freeline Therapeutics with a buy rating

Mizuho analyst Difei Yang has initiated Freeline Therapeutics (FRLN) with a buy rating and a $27 price target.Yang says that a Mizuho survey suggests that the company's lead program in hemophilia B, FLT180a, has strong commercial potential "given superior factor activity levels achieved by pa...

FRLN - Freeline Appoints Colin Love, PhD to Board of Directors

LONDON, March 11, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative gene therapies for patients suffering from inherited systemic debilitating...

FRLN - Freeline to Present at Upcoming Investor Conferences

LONDON, March 02, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative gene therapies for patients suffering from inherited systemic debilitating...
Previous 10 Next 10